Discovery of novel Cyclophilin D inhibitors starting from three dimensional fragments with millimolar potencies

[1]  D. Speicher,et al.  Cyclophilin: a specific cytosolic binding protein for cyclosporin A. , 1984, Science.

[2]  Hwa-Young Kim,et al.  Crystal structure of calcineurin–cyclophilin–cyclosporin shows common but distinct recognition of immunophilin–drug complexes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[3]  P. Taylor,et al.  Structures of immunophilins and their ligand complexes. , 2003, Current topics in medicinal chemistry.

[4]  H. Ke,et al.  Crystal structures of cyclophilin and its partners. , 2004, Frontiers in Bioscience.

[5]  M. Eisen.  All motifs are NOT created equal: structural properties of transcription factor-DNA interactions and the inference of sequence specificity , 2005, Genome Biology.

[6]  Francis Müller,et al.  Crystal engineering yields crystals of cyclophilin D diffracting to 1.7 A resolution. , 2005, Acta crystallographica. Section D, Biological crystallography.

[7]  P. Bernardi,et al.  Genetic Dissection of the Permeability Transition Pore , 2005, Journal of bioenergetics and biomembranes.

[8]  P. Richardson,et al.  A fluorescence polarization-based assay for peptidyl prolyl cis/trans isomerase cyclophilin A. , 2006, Analytical biochemistry.

[9]  Jean-François Guichou,et al.  Structure-based design, synthesis, and biological evaluation of novel inhibitors of human cyclophilin A. , 2006, Journal of medicinal chemistry.

[10]  Jan Schultz,et al.  Integration of fragment screening and library design. , 2007, Drug discovery today.

[11]  Luhua Lai,et al.  Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach. , 2009, Journal of medicinal chemistry.

[12]  E. Eisenmesser,et al.  Structural and Biochemical Characterization of the Human Cyclophilin Family of Peptidyl-Prolyl Isomerases , 2010, PLoS biology.

[13]  Elena Bisetto,et al.  Cyclophilin D in mitochondrial pathophysiology. , 2010, Biochimica et biophysica acta.

[14]  Martin Stahl,et al.  Rationalizing Tight Ligand Binding through Cooperative Interaction Networks , 2011, J. Chem. Inf. Model..

[15]  P. Gallay,et al.  Cyclophilin Inhibitors: An Emerging Class of Therapeutics for the Treatment of Chronic Hepatitis C Infection , 2012, Viruses.

[16]  J. Molkentin,et al.  Physiologic functions of cyclophilin D and the mitochondrial permeability transition pore. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[17]  A. Hopkins,et al.  The role of ligand efficiency metrics in drug discovery , 2014, Nature Reviews Drug Discovery.

[18]  J. Pawlotsky,et al.  Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities , 2016, Nature Communications.

[19]  R. Sutton,et al.  Small Molecule Inhibitors of Cyclophilin D To Protect Mitochondrial Function as a Potential Treatment for Acute Pancreatitis. , 2016, Journal of medicinal chemistry.

[20]  J. Pawlotsky,et al.  Small-molecule inhibitors of cyclophilins block opening of the mitochondrial permeability transition pore and protect mice from hepatic ischemia-reperfusion injury. , 2019, Gastroenterology.

[21]  Anna K H Hirsch,et al.  Concepts and Core Principles of Fragment-Based Drug Design , 2019, Molecules.